ExchangeDEX+

Buy Crypto Markets Spot FuturesGOLD Earn Event Center

Commodity Zero-Fee Gala

Intellia Therapeutics, Inc. (NTLA)

NASDAQ

$11.62

$-0.36

(-3.00%)

Intellia Therapeutics, Inc. (NTLA) Live Price Chart

Page last updated: 2026-02-12 21:46:00

Key Market Data

Market Cap	$1.35B
Open	$11.88
High	$202.73
Low	$5.90
Previous Close	$12.00
Price Change	$-0.36
Percentage Change	-3.00%
Volume	3M

Intellia Therapeutics, Inc. (NTLA) Stock Price Today

Intellia Therapeutics, Inc. (NTLA) is currently trading at $11.62 as of 2026-02-12 21:46:00, reflecting a -3.00% move ($-0.36) from the previous close.

In the short term, the stock has returned -332.78% over the past four weeks. Over the last 12 months, Intellia Therapeutics, Inc. has recorded a +22.19% price change, indicating a strong performance relative to the broader market.

Intellia Therapeutics, Inc. (NTLA) 7-Day Stock Price Changes

Over the past seven days, Intellia Therapeutics, Inc. has traded within a short-term range shaped by market sentiment in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector. During this period, the stock moved from its previous closing price of $11.32 to the latest recorded price of $11.62, reflecting an intraday change of -3.00%. Daily movements highlight shifts in trading volume (2,930,263), investor positioning, and reactions to macroeconomic updates.

From a momentum standpoint, NTLA has delivered a -332.78% return over the past month and a +22.19% change in the last 12 months, indicating a strong trend relative to its broader sector peers.

How to Buy Intellia Therapeutics, Inc. (NTLA)

You can buy and trade NTLA on MEXC in three simple steps:

Step 1: Create and Verify Your MEXC Account

Sign up on MEXC and complete the required identity verification (KYC). This ensures full access to trading features and secure funding options.

Step 2: Deposit Funds Into Your Account

Choose your preferred payment method to add USDT or other supported assets to your MEXC wallet. Depositing crypto is the fastest way to get started.

Step 3: Search for NTLA and Execute Your Trade

Open the trading page, enter NTLA in the search bar, select the amount of NTLA you would like to purchase. Place a market order for instant execution or a limit order to buy at your target price.

What is Intellia Therapeutics, Inc. (NTLA)?

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics, Inc. Information

Industry	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees	598
Sector	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Company Website	https://www.intelliatx.com

Frequently Asked Questions (FAQ)

1.What is the current share price of Intellia Therapeutics, Inc.?

The latest trading price for Intellia Therapeutics, Inc. (Common Stock) is $ 11.62, compared with a previous closing price of $ 12.00. That means the stock has moved -3.00% so far today. Intraday price updates and recent trading activity for NTLA can be tracked on the live chart and quote section on this page.

2.Is Intellia Therapeutics, Inc. stock going up or down?

Looking at recent performances, NTLA has returned -332.78% over the past month, +8.29% over the last six months and +22.19% over the past year. These figures capture share-price changes only, not the impact of dividends. Together they describe strong price momentum for Intellia Therapeutics, Inc. stock, but keep in mind that past returns do not guarantee future results.

3.Where does NTLA currently sit relative to its 52-week high and low?

In the most recent 52-week period, Intellia Therapeutics, Inc. has traded between a low of $ 5.90 and a high of $ 28.25. This 52-week range helps show where today's share price sits relative to its recent highs and lows, and is often used by investors to judge stock volatility, potential support and resistance levels, and whether NTLA is currently nearer the top or the bottom of its one-year trading band.

4.How is Intellia Therapeutics, Inc. classified by sector and industry?

Intellia Therapeutics, Inc. is classified in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector. In practice, this means Intellia Therapeutics, Inc. is grouped with other companies that serve similar end-markets and operate under comparable competitive and regulatory conditions. For investors, knowing NTLA’s sector helps with portfolio diversification, peer comparisons, and understanding how broader trends affecting the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector could influence Intellia Therapeutics, Inc.’s performance.

5.Where is Intellia Therapeutics, Inc. listed and how large is it by market value?

Intellia Therapeutics, Inc. is listed on the NASDAQ stock exchange in United States. Based on a market capitalization of $ 1.35B, the company is classified as a Small-cap stock. Market cap gives a quick sense of Intellia Therapeutics, Inc.'s size and importance in the equity market and is often used by investors and index providers when constructing portfolios or benchmarks.

6.What does NTLA's EPS tell investors about its profitability?

Trailing-twelve-month EPS of $ -3.85 summarises how much profit Intellia Therapeutics, Inc. has generated per share over the last year. Rising EPS over time can signal improving profitability or effective share repurchases, while flat or declining EPS may point to slower growth or margin pressure. EPS is a key input into valuation metrics such as P/E and is often monitored closely around earnings announcements.

7.How can I track Intellia Therapeutics, Inc.'s financial performance over time?

To follow Intellia Therapeutics, Inc.'s financial performance, investors typically review its quarterly and annual reports, which include detailed income statements, balance sheets and cash-flow statements. Combining these filings with key market data shown on this page—such as share price trends, P/E and dividend yield—provides a more complete view of how NTLA is performing and how the market is responding.

8.When is Intellia Therapeutics, Inc. expected to report earnings?

Intellia Therapeutics, Inc.'s next scheduled earnings release is currently expected on -- (the date may be updated by the company). Earnings announcements often act as important catalysts for NTLA, as they provide updated information on revenue, profitability and management's outlook.

9.What usually comes out in Intellia Therapeutics, Inc.'s earnings reports?

Intellia Therapeutics, Inc.'s earnings reports typically include headline figures such as revenue, net income and EPS, along with commentary on segment performance, margins, cash flow and guidance for future periods. Investors compare these results with market expectations and prior periods to assess whether NTLA is meeting, beating or missing expectations.

10.How can I stay informed about Intellia Therapeutics, Inc.'s results and guidance?

You can stay up to date on Intellia Therapeutics, Inc. by reviewing its quarterly earnings releases, listening to or reading transcripts of earnings calls, and following company news and filings. Pairing this fundamental information with the price and return data for NTLA on this page helps you see how new information is being reflected in the stock.

11.Does Intellia Therapeutics, Inc. pay a regular cash dividend to its shareholders?

Intellia Therapeutics, Inc. Non-paying. Based on the latest information, the stock has an indicated annual cash dividend of -- per share and a current dividend yield of 0 at the recent share price. Dividends are typically paid --, although the board can change the dividend policy at any time. Income-focused investors often monitor NTLA's dividend level, payment frequency and any announcements about future dividends when assessing the stock's appeal as a dividend-paying investment.

12.What are the current dividend yield and dividend payout ratio for NTLA?

Based on the latest earnings data, NTLA has a dividend yield of 0 and a dividend payout ratio of 0. The dividend yield shows how much cash return an investor receives from dividends each year relative to the current share price, helping assess whether Intellia Therapeutics, Inc. is an attractive income stock. The dividend payout ratio measures what percentage of earnings Intellia Therapeutics, Inc. distributes to shareholders as dividends versus how much it retains to reinvest in the business, which is an important indicator of dividend sustainability and room for future dividend growth.

13.What kind of business is Intellia Therapeutics, Inc.?

Intellia Therapeutics, Inc. is a publicly traded company in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry within the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector. It generates revenue from products and services related to this core business area, and investors can find a detailed description of its operations, strategy and geographic exposure in the company's annual report and other regulatory filings.

14.How is NTLA valued in terms of P/E ratio and EPS?

Intellia Therapeutics, Inc. currently trades at a price-to-earnings (P/E) ratio of --, based on trailing-twelve-month earnings per share (EPS) of $ -3.85. P/E is calculated by dividing the share price by EPS and shows how much investors are paying today for each unit of Intellia Therapeutics, Inc.'s earnings. Comparing NTLA's P/E and EPS to those of other IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES companies can help investors judge whether its valuation looks rich or attractive.

Explore More US Stocks

Stocks in the Same Sector

Browse other US stocks in the same sector as Intellia Therapeutics, Inc.

The Walt Disney Company

DIS

Largest Market Cap

See US stocks with the highest market capitalization

Most Actively Traded

Discover today's most actively traded US stocks

EIX

FSM

Top Gainers

Browse today's leading gainers in the US stock market

Haoxin Holdings Limited

HXHX

IPG Photonics Corporation

IPGP

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

BTC

ETH

SOL

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

NTLA-to-USD Calculator

Amount

NTLA

USD

1 NTLA = 11.62 USD